| Edinburgh University, Bachelor | |
| Molecular Biology | |
| Cambridge University., Ph.D | |
| Pathology |
Kevin Johnson is a Partner at Index Ventures working out of the London office. Prior to that he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio. Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer. Kevin led both the development of CAT’s platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development, including the first such drug, Humira™ to reach the market. He was also part of the management team that floated CAT on the London Stock Exchange (main market). Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.
